Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a analysis of a randomised phase III study.

Abstract

Authors

• Jing Li
  Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
• Changzheng Wang
  Department of Respiratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
• Chuntao Liu
  Department of Respiratory Disease, West China Hospital, Sichuan University, Sichuan, China.
• Jian Kang
  Institute of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China.
• Lingfei Kong
  Department of Pathology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
• Yijiang Huang
  Department of Respiratory Disease, Hainan General Hospital, Hainan Clinical Medicine Research Institution, Hainan, China.
• Shuang Liu
  Key Laboratory for Applied Technology of Sophisticated Analytical Instruments of Shandong Province, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, 250014, China.
• Mao Huang
  Department of Respiratory Disease, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
• Lu Wang
  Department of Laboratory, Akesu Center of Disease Control and Prevention, Akesu, China.
• Robert Fogel
  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
• Xavier Jaumont
  Novartis Pharma AG, Basel, Switzerland.
• Jing Yang
  Beijing Novartis Pharma Co. Ltd., Beijing, China.
• Nanshan Zhong
  Guangzhou National Laboratory, Guangzhou, China.

Keywords

No keywords available for this article.

External Resources